Availability and Cost
Dupilumab is available in 200 mg/1.14 mL and 300 mg/2 mL pre-filled syringes for self-administration. The estimated cost for dupilumab is approximately $30,000 per year. The manufacturer provides patient access support through their Dupixent® My Way program. Details of the program are available at https://www.dupixenthcp.com/. In their treatment guideline, Boguniewicz and colleagues provide readers with a table of recommendations for documentation to include when prescribing dupilumab in order to facilitate meeting the requirements for insurance coverage. Additional suggestions for wording appeal letters to insurers is included in the commentary accompanying the article.
Pediatr Pharm. 2019;25(6) © 2019 University of Virginia